Publisher
Springer Science and Business Media LLC
Reference17 articles.
1. Alsamman K, El-Masry OS (2018) Interferon regulatory factor 1 inactivation in human cancer. Biosci Rep 38(3):BSR20171672. https://doi.org/10.1042/BSR20171672/57646
2. Antonczyk A, Krist B, Sajek M, Michalska A, Piaszyk-Borychowska A, Plens-Galaska M, Wesoly J, Bluyssen HAR (2019) Direct inhibition of IRF-dependent transcriptional regulatory mechanisms associated with disease. Front Immunol 10(MAY):1–23. https://doi.org/10.3389/fimmu.2019.01176
3. Harada H, Fujita T, Miyamoto M, Kimura Y, Maruyama M, Furia A, Miyata T, Taniguchi T (1989) Structurally similar but functionally distinct factors, IRF-1 and IRF-2, bind to the same regulatory elements of IFN and IFN-inducible genes. Cell 58(4):729–739. https://doi.org/10.1016/0092-8674(89)90107-4
4. Hill M, MacLennan K, Cunningham D, Vaughan Hudson B, Burke M, Clarke P, Di Stefano F, Anderson L, Vaughan Hudson G, Mason D, Selby P, Linch D (1996) Prognostic significance of BCL-2 expression and BCL-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin’s lymphoma: a British National Lymphoma Investigation Study. Blood 88(3):1046–1051. https://doi.org/10.1182/blood.v88.3.1046.1046
5. Kröger A, Ortmann D, Krohne TU, Mohr L, Blum HE, Hauser H, Geissler M (2001) Growth suppression of the hepatocellular carcinoma cell line hepa1-6 by an activatable interferon regulatory factor-1 in mice. Cancer Res 61(6):2609–2617